MCID: EST001
MIFTS: 45

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 11 14 16

Classifications:



External Ids:

Disease Ontology 11 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

Disease Ontology: 11 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary: Estrogen-Receptor Positive Breast Cancer is related to breast cancer and endometrial hyperplasia. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Gene expression (Transcription) and Disease. The drugs Cyclophosphamide and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 456)
# Related Disease Score Top Affiliating Genes
1 breast cancer 31.1 TP53 PGR MIR125A KDM4C HSPB8 H2AC18
2 endometrial hyperplasia 30.9 TP53 PGR ESR1 CYP19A1 CCND1
3 vaginal discharge 30.8 PGR ESR1 CYP19A1
4 tubular adenocarcinoma 30.7 PGR ESR1 ERBB2
5 postmenopausal atrophic vaginitis 30.7 ESR1 CYP19A1
6 cribriform carcinoma 30.6 PGR ESR1 ERBB2 EGFR
7 body mass index quantitative trait locus 11 30.6 TP53 MIR125A KDM4C H2AC18 ESR1 CYP19A1
8 exanthem 30.6 H2AC18 ERBB2 EGFR AKT1
9 mucinous adenocarcinoma 30.6 U2AF1 TP53 ERBB2 EGFR
10 bilateral breast cancer 30.6 TP53 PGR ESR1 ERBB2 CYP19A1
11 adenocarcinoma 30.6 TP53 ERBB2 EGFR CDK4 CCND1 AKT1
12 sporadic breast cancer 30.5 TP53 PGR H2AC18 ESR1 ERBB2
13 small cell cancer of the lung 30.5 TP53 EGFR AKT1
14 premature menopause 30.4 TP53 PGR ESR1 ERBB2 CYP19A1 AKT1
15 ductal carcinoma in situ 30.4 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
16 in situ carcinoma 30.4 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
17 breast disease 30.3 U2AF1 TP53 PGR MIR125A KDM4C H2AC18
18 hypertrophy of breast 30.3 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
19 breast ductal carcinoma 30.3 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
20 estrogen-receptor negative breast cancer 30.3 TP53 PGR H2AC18 ESR1 ERBB2 EGFR
21 adenoid cystic carcinoma 30.2 TP53 PGR ERBB2 EGFR CDK4 CCND1
22 lung cancer susceptibility 3 30.2 U2AF1 TP53 MIR125A H2AC18 ERBB2 EGFR
23 female breast cancer 30.2 TP53 PGR ESR1 ERBB2 EGFR CYP19A1
24 endometrial cancer 29.9 TP53 PGR H2AC18 ESR1 ERBB2 EGFR
25 ovarian cancer 29.8 TP53 PGR MIR125A H2AC18 ESR1 ERBB2
26 breast adenocarcinoma 29.8 U2AF1 TP53 PGR H2AC18 ESR1 ERBB2
27 down syndrome 10.8
28 uterine corpus adenosarcoma 10.5 PGR ESR1
29 factor vii deficiency 10.5
30 ovarian cyst 10.4 PGR ESR1 CYP19A1
31 adult cystic nephroma 10.4 PGR ESR1
32 vagina leiomyosarcoma 10.4 PGR ESR1
33 scirrhous adenocarcinoma 10.4 PGR ERBB2
34 vulvar benign neoplasm 10.4 PGR ESR1
35 nipple carcinoma 10.4 PGR ESR1 ERBB2
36 breast mucinous cystadenocarcinoma 10.4 PGR ESR1 ERBB2
37 breast fibroadenosis 10.4 PGR ESR1 ERBB2
38 lipid-rich breast carcinoma 10.4 PGR ERBB2
39 bulbospinal polio 10.4 PGR ESR1 ERBB2
40 spinal polio 10.4 PGR ESR1 ERBB2
41 her2-receptor negative breast cancer 10.4 PGR ERBB2
42 diffuse peritoneal leiomyomatosis 10.4 PGR ESR1 CYP19A1
43 glycogen-rich clear cell breast carcinoma 10.4 PGR ESR1 ERBB2
44 peritoneal benign neoplasm 10.4 PGR ESR1 CYP19A1
45 breast cystic hypersecretory carcinoma 10.4 PGR ESR1 ERBB2
46 oncocytic breast carcinoma 10.4 PGR ESR1 ERBB2
47 breast squamous cell carcinoma 10.4 PGR ESR1 ERBB2
48 progesterone resistance 10.4 PGR ESR1
49 adenosquamous breast carcinoma 10.4 TP53 PGR
50 leiomyomatosis 10.4 PGR KDM4C ESR1

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

25 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.16 EGFR
2 Decreased viability GR00055-A-2 10.16 EGFR
3 Decreased viability GR00107-A-1 10.16 HSPB8
4 Decreased viability GR00221-A-1 10.16 AKT1 EGFR ESR1 HSPB8
5 Decreased viability GR00221-A-2 10.16 AKT1 ESR1
6 Decreased viability GR00221-A-3 10.16 AKT1 ERBB2
7 Decreased viability GR00221-A-4 10.16 AKT1 EGFR ERBB2 ESR1 HSPB8
8 Decreased viability GR00249-S 10.16 AKT1
9 Decreased viability GR00301-A 10.16 HSPB8
10 Decreased viability GR00386-A-1 10.16 ESR1
11 Decreased viability GR00402-S-2 10.16 ESR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.81 U2AF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.81 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.81 U2AF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.81 U2AF1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.81 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.81 ERBB2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.81 CBFB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.81 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.81 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.81 U2AF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.81 AKT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.81 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.81 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.81 CBFB
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.81 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.81 CBFB
28 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.81 AKT1 ERBB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.81 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.81 AKT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.81 CBFB
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.81 AKT1 CDK4 EGFR ERBB2 U2AF1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.81 ERBB2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.81 CBFB
35 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.81 U2AF1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.81 EGFR U2AF1
37 Increased cell viability after pRB stimulation GR00230-A-1 9.26 AKT1 CDK4 EGFR ERBB2

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
2 neoplasm MP:0002006 10.26 AKT1 CBFB CCND1 CDK4 EGFR ERBB2
3 normal MP:0002873 10.21 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
4 endocrine/exocrine gland MP:0005379 10.2 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
5 cellular MP:0005384 10.18 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
6 immune system MP:0005387 10.17 AKT1 CBFB CCND1 CDK4 CYP19A1 CYP2D6
7 muscle MP:0005369 10.15 AKT1 CDK4 CYP19A1 EGFR ERBB2 ESR1
8 cardiovascular system MP:0005385 10.15 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
9 digestive/alimentary MP:0005381 10.03 CBFB CCND1 CDK4 CYP19A1 EGFR ERBB2
10 respiratory system MP:0005388 9.86 AKT1 CBFB CCND1 EGFR ERBB2 ESR1
11 skeleton MP:0005390 9.85 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
12 hematopoietic system MP:0005397 9.77 AKT1 CBFB CCND1 CDK4 CYP19A1 EGFR
13 integument MP:0010771 9.47 AKT1 CBFB CCND1 CDK4 CYP19A1 CYP2D6

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
3
Epirubicin Approved Phase 4 56420-45-2 41867
4
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
5 Tubulin Modulators Phase 4
6 Antineoplastic Agents, Alkylating Phase 4
7 Antimitotic Agents Phase 4
8 Antirheumatic Agents Phase 4
9 Immunosuppressive Agents Phase 4
10 Antibiotics, Antitubercular Phase 4
11 Anti-Bacterial Agents Phase 4
12 Immunologic Factors Phase 4
13 Alkylating Agents Phase 4
14
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
15
Exemestane Approved, Investigational Phase 2, Phase 3 107868-30-4 60198
16
Anastrozole Approved, Investigational Phase 2, Phase 3 120511-73-1 2187
17
Tamoxifen Approved Phase 2, Phase 3 10540-29-1, 54965-24-1 2733526
18
Capecitabine Approved, Investigational Phase 2, Phase 3 154361-50-9 60953
19
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
20
Tryptophan Approved, Nutraceutical, Withdrawn Phase 3 73-22-3 6305
21 Citrate Phase 3
22 Antidepressive Agents Phase 3
23 Psychotropic Drugs Phase 3
24 Antineoplastic Agents, Hormonal Phase 2, Phase 3
25 Estrogen Receptor Modulators Phase 2, Phase 3
26 Selective Estrogen Receptor Modulators Phase 2, Phase 3
27
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
28
Simvastatin Approved Phase 2 79902-63-9 54454
29
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
30
Zoledronic acid Approved Phase 2 118072-93-8 68740
31
Lenograstim Approved, Investigational Phase 2 135968-09-1
32
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
33
Busulfan Approved, Investigational Phase 2 55-98-1 2478
34
Melphalan Approved Phase 2 148-82-3 4053 460612
35
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
36
Sargramostim Approved, Investigational Phase 2 123774-72-1
37
Aldesleukin Approved Phase 2 110942-02-4
38
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
41
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
42
Avelumab Approved, Investigational Phase 2 1537032-82-8
43
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181
44
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
45
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
46
Polyestradiol phosphate Approved Phase 2 28014-46-2
47
Caffeine Approved Phase 2 58-08-2 2519
48
Calcium polycarbophil Approved Phase 2 126040-58-2
49
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial Not yet recruiting NCT04137640 Phase 4 palbociclib combined with letrozole;epirubicin combined with cyclophosphamide and sequential docetaxel
2 A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Completed NCT00265759 Phase 3 anastrozole;exemestane;letrozole
3 A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer Active, not recruiting NCT02947685 Phase 3 palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
4 A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
5 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
6 Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
7 A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer Unknown status NCT02216786 Phase 2 AZD2014;Everolimus;Fulvestrant
8 Letrozole With or Without Metronomic Capecitabine in First Line Treatment of Patients With ER-positive HER2 Negative Advanced Breast Cancer: A Randomized Phase II Study. Unknown status NCT04571437 Phase 2 Capecitabine;Letrozole 2.5mg
9 Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients Unknown status NCT00954135 Phase 2 letrozolo+cyclophosphamide;letrozolo+sorafenib+cyclophosphamide
10 Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
11 Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed NCT02988986 Phase 2 TAK-228;Tamoxifen
12 Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy. Completed NCT02015559 Phase 2 mucoadhesive oral wound rinse
13 A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Completed NCT01194440 Phase 2 letrozole;zoledronic acid
14 Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II Completed NCT00407888 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel albumin-stabilized nanoparticle formulation
15 A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor Completed NCT00676663 Phase 2 entinostat;exemestane;Placebo
16 A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
17 A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer Completed NCT00057941 Phase 2 anastrozole;gefitinib;fulvestrant
18 A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer Completed NCT00602043 Phase 2
19 A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer Completed NCT00082810 Phase 2 fulvestrant;tipifarnib
20 A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
21 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
22 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
23 A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
24 A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI) Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
25 A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0). Completed NCT00093002 Phase 2 Fulvestrant
26 Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane Completed NCT01231659 Phase 2 Everolimus;Letrozole
27 A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients Completed NCT01605396 Phase 2 Ridaforolimus;Dalotuzumab;Exemestane
28 A Phase 2 Study of VLS-101 in Patients With Solid Tumors Recruiting NCT04504916 Phase 2 Zilovertamab vedotin
29 Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition Recruiting NCT04965688 Phase 2 Drug determined by treating oncologist based on recommendation from systems biology analysis.
30 Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer Recruiting NCT05076695 Phase 2 Palbociclib;trastuzumab;pyrotinib;fulvestrant
31 A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT Study Recruiting NCT03573648 Phase 2 Avelumab;Endocrine therapy;Palbociclib
32 T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy Active, not recruiting NCT02957968 Phase 2 Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
33 A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer Active, not recruiting NCT03633331 Phase 2 Palbociclib;Letrozole;Fulvestrant
34 A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016 Active, not recruiting NCT02668666 Phase 2 Palbociclib;Tamoxifen
35 PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer Active, not recruiting NCT02238808 Phase 2 Estradiol
36 A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor Active, not recruiting NCT01992952 Phase 1, Phase 2 AZD5363;Placebo;Fulvestrant
37 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Active, not recruiting NCT01984138 Phase 2 ESTRING;Replens
38 [18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer Active, not recruiting NCT02409316 Phase 2 [18F]FES
39 A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer Active, not recruiting NCT03395899 Phase 2 Atezolizumab;Cobimetinib;Ipatasertib;Bevacizumab
40 A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Active, not recruiting NCT03250676 Phase 1, Phase 2 H3B-6545
41 A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer Not yet recruiting NCT05020860 Phase 2 Paclitaxel;Carboplatin;Trastuzumab;Pertuzumab;Doxorubicin;Cyclophosphamide
42 A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer Suspended NCT03831711 Phase 1, Phase 2 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
43 Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer Suspended NCT02778685 Phase 2 Fulvestrant;Letrozole;Palbociclib
44 A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) Terminated NCT02000375 Phase 2 DHEA
45 Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer Terminated NCT02269670 Phase 2 everolimus;anastrozole;letrozole;tamoxifen citrate;fulvestrant;megestrol acetate
46 Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer Terminated NCT01394211 Phase 2 anastrozole;pazopanib hydrochloride
47 A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer Terminated NCT01368263 Phase 2 goserelin acetate;letrozole;anastrozole;chemotherapy
48 Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study Terminated NCT00194792 Phase 2 exemestane;triptorelin pamoate;capecitabine;methotrexate;vinorelbine tartrate;paclitaxel
49 Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma Terminated NCT02273752 Phase 2 Everolimus
50 An Open-Label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Terminated NCT01823835 Phase 1, Phase 2 GDC-0810;LHRH Agonist;Palbociclib

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

Organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

MalaCards : Breast, Bone, Lymph Node, Bone Marrow, Prostate, T Cells, Endothelial

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 1477)
# Title Authors PMID Year
1
One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer. 62
36244388 2022
2
ASO Visual Abstract: Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen Receptor-Positive Breast Cancer. 62
35980550 2022
3
Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography. 62
36243494 2022
4
Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway. 62
36241702 2022
5
Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer. 62
35776258 2022
6
Dietary exposure to acrylamide and breast cancer risk: results from the NutriNet-Santé cohort. 62
36055962 2022
7
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. 62
35729220 2022
8
The ubiquitin ligase RNF2 stabilizes ERα and modulates breast cancer progression. 62
36271315 2022
9
Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models. 62
35119458 2022
10
Stabilization of estrogen receptor α by USP37 contributes to the progression of breast cancer. 62
36221793 2022
11
Molecular testing opportunities on cytology effusion specimens: the pre-analytic effects of various body fluid cytology preparation methods on RNA extraction quality and targeted sequencing. 62
36270909 2022
12
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. 62
36071033 2022
13
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. 62
35442755 2022
14
A novel oncogenic enhancer of estrogen receptor-positive breast cancer. 62
36159594 2022
15
Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα. 62
36070108 2022
16
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor. 62
35977350 2022
17
Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. 62
36031754 2022
18
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer. 62
36042494 2022
19
Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer. 62
35412846 2022
20
The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. 62
35927391 2022
21
Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. 62
36008376 2022
22
Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. 62
35653148 2022
23
MiR-4458-loaded gelatin nanospheres target COL11A1 for DDR2/SRC signaling pathway inactivation to suppress the progression of estrogen receptor-positive breast cancer. 62
35792605 2022
24
The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. 62
35568265 2022
25
Molecular Characterization of Exosomes for Subtype-Based Diagnosis of Breast Cancer. 62
35802880 2022
26
Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia. 62
35524760 2022
27
HSF1 Can Prevent Inflammation following Heat Shock by Inhibiting the Excessive Activation of the ATF3 and JUN&FOS Genes. 62
36010586 2022
28
Establishment and transcriptome characterization of tamoxifen-resistant canine mammary gland tumor cells. 62
35193047 2022
29
Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology. 62
35688518 2022
30
Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer. 62
35732800 2022
31
High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer. 62
35813014 2022
32
Screening of and mechanism underlying the action of serum- and glucocorticoid-regulated kinase 3-targeted drugs against estrogen receptor-positive breast cancer. 62
35569550 2022
33
The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor-positive breast cancer. 62
35415910 2022
34
PET Imaging of Estrogen Receptors for Gynecological Tumors. 62
35675139 2022
35
Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis. 62
35426541 2022
36
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation. 62
35616371 2022
37
Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor-positive breast cancer via regulation of the mTOR pathway. 62
35757841 2022
38
FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer. 62
35447603 2022
39
Exploiting Mouse Models to Recapitulate Clinical Tumor Dormancy and Recurrence in Breast Cancer. 62
35560214 2022
40
Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity. 62
35814932 2022
41
LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway. 62
35657638 2022
42
A Telehealth-Delivered Tai Chi Intervention (TaiChi4Joint) for Managing Aromatase Inhibitor-Induced Arthralgia in Patients With Breast Cancer During COVID-19: Longitudinal Pilot Study. 62
35727609 2022
43
PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. 62
35187951 2022
44
Severe Hyponatremia During First Cycle of Cyclophosphamide/Doxorubicin Chemotherapy. 62
35584371 2022
45
Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy. 62
35213039 2022
46
The potential implications of estrogenic and antioxidant-dependent activities of high doses of methyl paraben on MCF7 breast cancer cells. 62
35174924 2022
47
Role of Lipoproteins in the Pathophysiology of Breast Cancer. 62
35629858 2022
48
Estrogen for the Treatment and Prevention of Breast Cancer: A Tale of 2 Karnofsky Lectures. 62
35594462 2022
49
Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer. 62
35583138 2022
50
Spine‑specific downregulation of LAPTM5 expression promotes the progression and spinal metastasis of estrogen receptor‑positive breast cancer by activating glutamine‑dependent mTOR signaling. 62
35294039 2022

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 AKT1 CBFB CCND1 CDK4 EGFR ERBB2
2
Show member pathways
13.81 TP53 H2AC18 ESR1 ERBB2 EGFR CYP19A1
3 13.66 AKT1 CBFB CCND1 CDK4 EGFR ERBB2
4
Show member pathways
12.9 PGR H2AC18 ESR1 EGFR CCND1 CBFB
5 12.83 PGR ESR1 ERBB2 EGFR AKT1
6
Show member pathways
12.77 AKT1 CCND1 EGFR H2AC18 TP53
7 12.68 AKT1 CCND1 CDK4 EGFR TP53
8
Show member pathways
12.63 TP53 ERBB2 EGFR CDK4 CCND1 AKT1
9
Show member pathways
12.5 TP53 ERBB2 EGFR AKT1
10
Show member pathways
12.44 TP53 ERBB2 EGFR AKT1
11 12.43 TP53 CDK4 CCND1 AKT1
12
Show member pathways
12.41 ESR1 EGFR CCND1 AKT1
13
Show member pathways
12.4 TP53 ESR1 ERBB2 CCND1 AKT1
14
Show member pathways
12.37 PGR ESR1 CDK4 CCND1
15 12.28 ERBB2 EGFR CCND1 AKT1
16
Show member pathways
12.27 ESR1 ERBB2 EGFR CCND1 AKT1
17
Show member pathways
12.2 TP53 CDK4 CCND1 AKT1
18 12.18 TP53 EGFR CCND1 AKT1
19
Show member pathways
12.13 TP53 CDK4 CCND1 AKT1
20
Show member pathways
12.11 ERBB2 EGFR CCND1 AKT1
21 12.08 AKT1 EGFR ERBB2 TP53
22
Show member pathways
12.07 TP53 ERBB2 EGFR CDK4 CCND1 AKT1
23
Show member pathways
12.04 PGR ESR1 ERBB2 EGFR
24
Show member pathways
12.02 ERBB2 EGFR CDK4 CCND1 AKT1
25
Show member pathways
11.99 TP53 ERBB2 EGFR AKT1
26 11.95 TP53 EGFR CDK4 CCND1
27
Show member pathways
11.85 ESR1 ERBB2 EGFR
28 11.84 TP53 CDK4 CCND1 AKT1
29 11.83 TP53 CDK4 CCND1
30 11.75 ESR1 CBFB AKT1
31
Show member pathways
11.72 ESR1 EGFR CCND1
32 11.69 PGR ESR1 CCND1
33 11.68 ERBB2 EGFR AKT1
34 11.68 TP53 ESR1 EGFR CYP19A1 CDK4 CCND1
35 11.66 TP53 ERBB2 AKT1
36 11.66 TP53 CDK4 CCND1
37
Show member pathways
11.66 TP53 PGR ESR1 ERBB2 EGFR CDK4
38 11.65 TP53 CDK4 CCND1
39 11.65 KDM4C CCND1 AKT1
40 11.63 TP53 ESR1 CCND1 CBFB
41
Show member pathways
11.62 TP53 CCND1 AKT1
42 11.61 ESR1 EGFR CCND1 AKT1
43 11.59 TP53 CCND1 AKT1
44
Show member pathways
11.58 ERBB2 EGFR CCND1 AKT1
45 11.51 ESR1 CDK4 CCND1 CBFB
46 11.5 TP53 ERBB2 EGFR CDK4 CCND1 AKT1
47 11.48 TP53 CDK4 CCND1
48
Show member pathways
11.42 EGFR CCND1 AKT1
49 11.39 TP53 CDK4 AKT1
50 11.37 ERBB2 EGFR AKT1

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin D1-CDK4 complex GO:0097128 8.92 CDK4 CCND1

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.92 TP53 PGR MIR125A ESR1 AKT1
2 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.73 EGFR CCND1 AKT1
3 cellular response to epidermal growth factor stimulus GO:0071364 9.63 ERBB2 EGFR AKT1
4 positive regulation of miRNA maturation GO:1903800 9.37 TP53 EGFR
5 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.26 TP53 ESR1
6 response to UV-A GO:0070141 9.1 EGFR CCND1 AKT1

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.8 TP53 PGR KDM4C ESR1 EGFR CCND1
2 protein kinase activity GO:0004672 9.76 HSPB8 ERBB2 EGFR CDK4 CCND1 AKT1
3 nitric-oxide synthase regulator activity GO:0030235 9.1 ESR1 EGFR AKT1

Sources for Estrogen-Receptor Positive Breast Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....